Annovis Bio Inc ((ANVS)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Annovis Bio Inc. is conducting a clinical trial titled A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer’s Disease. The study aims to determine the effectiveness and safety of buntanetap/Posiphen in improving cognition and function in adults aged 55-85 with early Alzheimer’s disease.
The intervention being tested is a drug called buntanetap/Posiphen, administered as a 30mg capsule taken orally once daily for 18 months. The purpose is to assess its impact on cognitive and functional improvements compared to a placebo.
This Phase 3 interventional study employs a randomized, parallel assignment model with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are blinded. The primary goal is treatment efficacy.
The study began on February 4, 2025, with primary completion expected 18 months later. The latest update was submitted on June 30, 2025, indicating ongoing recruitment.
For investors, this study could significantly impact Annovis Bio Inc.’s stock performance, especially if results show positive efficacy and safety outcomes. The Alzheimer’s treatment market is competitive, and success here could enhance Annovis Bio’s position.
The study is currently recruiting, with further details available on the ClinicalTrials portal.